Incyte Corporation (INCY)
| Market Cap | 13.23B |
| Revenue (ttm) | 4.41B |
| Net Income (ttm) | 21.27M |
| Shares Out | 193.57M |
| EPS (ttm) | 0.10 |
| PE Ratio | 704.66 |
| Forward PE | 11.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,939,334 |
| Open | 70.98 |
| Previous Close | 70.81 |
| Day's Range | 67.82 - 71.12 |
| 52-Week Range | 53.56 - 83.95 |
| Beta | 0.68 |
| Analysts | Hold |
| Price Target | 73.81 (+7.96%) |
| Earnings Date | Jul 29, 2025 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]
Financial Performance
In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for INCY stock is "Hold." The 12-month stock price forecast is $73.81, which is an increase of 7.96% from the latest price.
News
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire.
Incyte Says FDA Extended Review Period for Opzelura
Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11.
Incyte Lymphoma Treatment Gets FDA Approval
Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD1...
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration t...
Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025.
Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
WILMINGTON, Del.--(BUSINESS WIRE)--Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025.
20 stocks primed for rapid growth while trading at half of Nvidia's valuation
When selecting investments, it is easy to get hung up on a particular metric, such as a dividend yield or a price ratio, but investors need to look deeper or they might miss opportunities.
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET). The presentation will ...
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States.
20 stocks of companies showing excellent earnings-season trends even as the economy cools
With U.S. economic growth turning negative during the first quarter, this earnings season's results might shed some light on which companies may best weather the disruption brought about by President ...
Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Office...
Incyte raises 2025 sales forecast for blood cancer drug after solid quarter
Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results.
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR25--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025.
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO25--Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 20...
These 20 worst-performing stocks in the S&P 500 sank 17% or more in March
Stocks turned higher on Monday afternoon to finish March on a positive note. Still, the S&P 500 ended with a 5.8% decline for March, with 69% of component stocks down for the month.
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitam...
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is ex...
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
Incyte Is Today's Worst S&P 500 Stock. Here's Why.
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years...